Compare Rush Street Interactive Inc (RSI) vs Summit Therapeutics Inc (SMMT) Price & Performance

Rush Street Interactive (RSI) trades at $20.32, up 0.4% on the day, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and revenue growth from $1.13B in 2025 to $1.4B in 2026. Analyst consensus is bullish with a $34.88 price target, though net income margin compression from 2.93% to 2.33% highlights profitability challenges.

RSI presents a mixed outlook: robust revenue growth and solid analyst support contrast with thin margins and bearish technicals. The stock offers upside to consensus targets but faces execution risks in a competitive online betting market. Investors should weigh growth potential against margin pressures and market sentiment.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.